Levofloxacin Drug Asset Due Diligence Report 2026

This Levofloxacin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

424

Registered trials

107

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Levofloxacin can convert its Small molecule drug profile and Bacterial Top II x Bacterial top IV biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Levofloxacin (query alias: levofloxacin)
Modality / target	Small molecule drug; Bacterial Top II x Bacterial top IV; Bacterial DNA gyrase inhibitors, Bacterial top IV inhibitors
Highest global status	Approved
Originator	Johnson & Johnson
Active developers	Daiichi Sankyo Co., Ltd., CHIESI Farmaceutici SpA, Ceolia Pharma Co., Ltd.

The MCP disease footprint includes Otitis Externa, Otitis Media, Cystic Fibrosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07624422	Phase 4	Not yet recruiting	150	H. pylori Eradication Rate
ChiCTR2600125592	Phase 4	Not yet recruiting	110	Palpebral conjunctiva congestion score
NCT07675954	Phase 3	Not yet recruiting	294	Favourable outcome at 12 months after treatment discontinuation

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

Phase 4; n=5; evaluation: not stated. Reported fields: Other (Not Including Serious) Adverse Events = 0 Participants ; -; -

Ciprofloxacin Versus Levofloxacin and Rate of Breakthrough Infections in Hematopoietic Stem Cell Transplant Patients

Phase 2; n=308; evaluation: not stated. Reported fields: Proportion of Bloodstream Bacterial Infections = 18 participants ; -; -

Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

Phase 4; n=94; evaluation: not stated. Reported fields: -; Cure/Control at 3 Months = 28 Participants ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Levofloxacin addresses Otitis Externa, Otitis Media, Cystic Fibrosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-04-01	跨国药企转让重磅原研药，“后集采时代”新玩法来了	Approved	Financial terms not disclosed
2011-12-21	Ranbaxy to Market Daiichi Sankyo’s Innovative Products in Malaysia Strategic Alliance Harnesses Synergies in ASEAN	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Levofloxacin hapten, antigen and antibody as well as preparation method and application of levofloxacin hapten, antigen and antibody”. The milestone feed surfaced a patent-application signal described as “Method for improving purity of levofloxacin product”. The milestone feed surfaced a patent-application signal described as “Levofloxacin ear drops with excellent biological adaptability as well as preparation method and application of levofloxacin ear drops”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO